Gillor: University Medical Centre Cologne; Munich: Prof. Dr. J. Bogner, B. Sonntag: University Hospital Munich; Regensburg: Prof. Dr. B. Salzberger: University Medical Centre Regensburg; MK0683 molecular weight Rostock: Dr. C. Fritzsche: University Clinic Rostock. “
“We present national trends in death

rates and the proportion of deaths attributable to AIDS in the era of effective antiretroviral therapy (ART), and examine risk factors associated with an AIDS-related death. Analyses of the national HIV-infected cohort for England and Wales linked to death records from the Office of National Statistics were performed. Annual all-cause mortality rates were calculated by age group and sex for the years 1999–2008 and rates for 2008 were compared with death rates in the general

population. Risk factors associated with an AIDS-related death were investigated using a case–control study design. The all-cause mortality rate among persons diagnosed with HIV infection aged 15–59 years fell over the decade: from 217 per 10 000 in 1999 to 82 per 10 000 in 2008, with declines in all age groups and exposure categories except women aged 50–59 years and persons who inject drugs (rate fluctuations in both of these groups were probably a result of small numbers). Compared with the general population (15 per 10 000 in 2008), death rates among persons diagnosed with HIV infection remained high, especially in younger persons (aged 15–29 years) and persons who inject drugs (13 and 20 times higher, respectively). AIDS-related this website deaths accounted for 43% of all deaths over the decade (24% in 2008). Late diagnosis (CD4 count < 350 cells/μL) was the most

important predictor of dying of AIDS [odds ratio (OR) 10.55; 95% confidence interval (CI) 8.22–13.54]. Sixty per cent of all-cause mortality and 81% of all AIDS-related deaths were attributable to late diagnosis. Despite substantial declines, Levetiracetam death rates among persons diagnosed with HIV infection continue to exceed those of the general population in the ART era. Earlier diagnosis could have prevented 1600 AIDS-related deaths over the decade. These findings highlight the need to intensify efforts to offer and recommend an HIV test in a wider range of clinical and community settings. “
“The aim of the study was to determine whether the chemokine (C-C motif) receptor 5 (CCR5) Δ32 deletion is associated with long-term response to combination antiretroviral treatment (cART) in HIV-1-infected patients. The genetic substudy of the Agence Nationale de Recherche sur le SIDA (ANRS) CO8 APROCO-COPILOTE cohort included 609 patients who started protease inhibitor-containing cART in 1997–1999. Patients were considered to have a sustained virological response if all plasma HIV RNA measurements in the period considered were <500 HIV-1 RNA copies/ml, allowing for a single blip. Virological response was compared between patients heterozygous for CCR5 Δ32 (Δ32/wt) and wild-type patients (wt/wt) from month 4 to year 3 and from month 4 to year 5.